Related Experiment Video
Updated: Jun 3, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
[Differential pharmacokinetic characteristics of micafungin. Experience in special populations]
Santiago Grau Cerrato1, Sonia Luque Pardos, Olivia Ferrández Quirante
1Servicio de Farmacia, Hospital del Mar, Barcelona, España. sgrau@hospitaldelmar.cat
Abstract:
Currently, three echinocandins are available for the treatment of fungal infections. Micafungin is the latest drug to be incorporated into this group of antifungal agents. Although the mechanism of action of micafungin is similar to that of other echinocandins, this molecule has certain pharmacokinetic characteristics that distinguish it from other drugs in this group. Nowadays, there is wide information on the pharmacokinetic behavior of micafungin, mainly from patients included in clinical trials. However, there is far less knowledge of the pharmacokinetics of this echinocandin in special populations. The aim of the current review was to analyze the available information on the pharmacokinetics of micafungin in pediatric patients, the elderly, patients with renal insufficiency or liver failure, and transplant recipient.
Related Concept Videos
Pharmacodynamic Models: Overview
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacokinetics in Pediatric Patients: Drug Excretion
Antifungal Agents
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

